Barclays on Collegium Pharmaceutical (COLL): 'we would add to positions at this level'
Tweet Send to a Friend
Barclays analyst Glen Santangelo reiterated an Overweight rating and $56.00 price target on Collegium Pharmaceutical (NASDAQ: COLL)The analyst commented, "Coming ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
